US5951974A
(en)
*
|
1993-11-10 |
1999-09-14 |
Enzon, Inc. |
Interferon polymer conjugates
|
GB9417742D0
(en)
*
|
1994-09-03 |
1994-10-19 |
Univ Nottingham |
Macrophage stimulating composition
|
US5738846A
(en)
*
|
1994-11-10 |
1998-04-14 |
Enzon, Inc. |
Interferon polymer conjugates and process for preparing the same
|
US5908621A
(en)
*
|
1995-11-02 |
1999-06-01 |
Schering Corporation |
Polyethylene glycol modified interferon therapy
|
PT858343E
(pt)
|
1995-11-02 |
2004-07-30 |
Schering Corp |
Terapia por infusao continua de uma dose baixa de citoquina
|
TW517067B
(en)
|
1996-05-31 |
2003-01-11 |
Hoffmann La Roche |
Interferon conjugates
|
US20030190307A1
(en)
*
|
1996-12-24 |
2003-10-09 |
Biogen, Inc. |
Stable liquid interferon formulations
|
US6472373B1
(en)
*
|
1997-09-21 |
2002-10-29 |
Schering Corporation |
Combination therapy for eradicating detectable HCV-RNA in antiviral treatment naive patients having chronic hepatitis C infection
|
US5981709A
(en)
*
|
1997-12-19 |
1999-11-09 |
Enzon, Inc. |
α-interferon-polymer-conjugates having enhanced biological activity and methods of preparing the same
|
US5985263A
(en)
*
|
1997-12-19 |
1999-11-16 |
Enzon, Inc. |
Substantially pure histidine-linked protein polymer conjugates
|
US6180096B1
(en)
|
1998-03-26 |
2001-01-30 |
Schering Corporation |
Formulations for protection of peg-interferon alpha conjugates
|
BR9909087A
(pt)
*
|
1998-03-26 |
2000-12-05 |
Schering Corp |
Formulações para proteção de conjugados peg-alfa interferon
|
PL193352B1
(pl)
*
|
1998-04-28 |
2007-02-28 |
Applied Research Systems |
Koniugat poliol-interferon ß, sposób jego wytwarzania i jego zastosowanie oraz kompozycja farmaceutyczna
|
EP0956861B1
(en)
*
|
1998-05-15 |
2002-04-24 |
Schering Corporation |
Combination therapy comprising ribavirin and interferon alpha in antiviral treatment naive patients having chronic hepatitis c infection
|
ITMI981148A1
(it)
*
|
1998-05-22 |
1999-11-22 |
Therapicon Srl |
Utilizzo di lisozima c modificato per preparare composizioni medicinali per il trattamento di alcune gravi malattie
|
PL192364B1
(pl)
*
|
1998-06-08 |
2006-10-31 |
Hoffmann La Roche |
Zastosowanie koniugatu PEG-IFN-α 2A w połączeniu z rybawiryną
|
CA2338665C
(en)
|
1998-08-06 |
2011-01-18 |
Mountain View Pharmaceuticals, Inc. |
Peg-urate oxidase conjugates and use thereof
|
US6783965B1
(en)
*
|
2000-02-10 |
2004-08-31 |
Mountain View Pharmaceuticals, Inc. |
Aggregate-free urate oxidase for preparation of non-immunogenic polymer conjugates
|
EA005005B1
(ru)
*
|
1998-10-16 |
2004-10-28 |
Байоджен, Инк. |
ГИБРИДНЫЙ ПОЛИПЕПТИД β1α-ИНТЕРФЕРОНА ЧЕЛОВЕКА, ЕГО МУТАНТНЫЕ ФОРМЫ И ПРОИЗВОДНЫЕ И СОДЕРЖАЩАЯ ИХ ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ
|
CN1329082C
(zh)
*
|
1998-10-16 |
2007-08-01 |
拜奥根Idec马萨诸塞公司 |
干扰素-β-1a的聚合物缀合物及其使用
|
US6824768B2
(en)
*
|
1998-12-18 |
2004-11-30 |
Schering Corporation |
Ribavirin-pegylated interferon alfa induction HCV combination therapy
|
PE20001548A1
(es)
*
|
1999-03-02 |
2001-01-16 |
Schering Corp |
Uso de interferon alfa pegilado para el tratamiento de vih-1
|
US6923966B2
(en)
|
1999-04-08 |
2005-08-02 |
Schering Corporation |
Melanoma therapy
|
TWI292320B
(en)
|
1999-04-08 |
2008-01-11 |
Schering Corp |
Melanoma therapy
|
US6605273B2
(en)
|
1999-04-08 |
2003-08-12 |
Schering Corporation |
Renal cell carcinoma treatment
|
PE20010288A1
(es)
|
1999-07-02 |
2001-03-07 |
Hoffmann La Roche |
Derivados de eritropoyetina
|
WO2001026677A1
(fr)
*
|
1999-10-12 |
2001-04-19 |
Santen Pharmaceutical Co., Ltd. |
Complexe a base d'interferon et son utilisation en medecine
|
TR200101086A3
(hu)
*
|
1999-10-15 |
2001-08-21 |
|
|
YU32402A
(sh)
|
1999-11-12 |
2005-03-15 |
Maxygen Holdings Ltd. |
Konjugati gama interferona
|
IL149267A0
(en)
|
1999-11-12 |
2002-11-10 |
Maxygen Holdings Ltd |
Interferon gamma conjugates
|
WO2001051510A2
(en)
|
2000-01-10 |
2001-07-19 |
Maxygen Holdings Ltd |
G-csf conjugates
|
EP1908477A3
(en)
*
|
2000-01-24 |
2008-06-11 |
Schering Corporation |
Combination of temozolomide and pegylated interferon-alpha for treating cancer
|
WO2001052882A1
(en)
*
|
2000-01-24 |
2001-07-26 |
Schering Corporation |
Combination of temozolomide and pegylated interferon-alpha for treating cancer
|
JP2003521930A
(ja)
|
2000-02-11 |
2003-07-22 |
マキシゲン・エイピーエス |
第VII因子または第VIIa因子様分子
|
US20020004584A1
(en)
*
|
2000-03-09 |
2002-01-10 |
Laughlin Mark A. |
HIV immune adjuvant therapy
|
US20030068792A1
(en)
*
|
2000-12-14 |
2003-04-10 |
Yiyou Chen |
Targeted enzymes
|
US20030147874A1
(en)
*
|
2000-12-14 |
2003-08-07 |
Volker Schellenberger |
Targeted enzyme prodrug therapy
|
US20030049689A1
(en)
*
|
2000-12-14 |
2003-03-13 |
Cynthia Edwards |
Multifunctional polypeptides
|
US20080248544A1
(en)
*
|
2000-12-14 |
2008-10-09 |
Murray Christopher J |
Methods And Compositions For Grafting Functional Loops Into A Protein
|
CZ20032526A3
(cs)
|
2001-02-27 |
2003-12-17 |
Maxygen Aps |
Nové molekuly podobné interferonu beta
|
US6958388B2
(en)
|
2001-04-06 |
2005-10-25 |
Maxygen, Aps |
Interferon gamma polypeptide variants
|
US7038015B2
(en)
*
|
2001-04-06 |
2006-05-02 |
Maxygen Holdings, Ltd. |
Interferon gamma polypeptide variants
|
UA78726C2
(en)
|
2001-11-01 |
2007-04-25 |
Sciclone Pharmaceuticals Inc |
Pharmaceutical composition of thymosin alpha 1 conjugated with polyethylene glycol, method for production, and method for treatment
|
WO2003049760A1
(en)
*
|
2001-12-07 |
2003-06-19 |
Intermune, Inc. |
Compositions and method for treating hepatitis virus infection
|
ME00239B
(me)
*
|
2002-01-18 |
2011-05-10 |
Biogen Ma Inc |
Polimerna jedinjenja polialkilena i njihova upotreba
|
DE10209821A1
(de)
|
2002-03-06 |
2003-09-25 |
Biotechnologie Ges Mittelhesse |
Kopplung von Proteinen an ein modifiziertes Polysaccharid
|
TW200400818A
(en)
|
2002-05-21 |
2004-01-16 |
Wyeth Corp |
Method for the use of pyranoindole derivatives to treat infection with hepatitis C virus
|
EP1517710B1
(en)
|
2002-06-21 |
2011-03-30 |
Novo Nordisk Health Care AG |
Pegylated factor vii glycoforms
|
TW200500375A
(en)
|
2002-06-28 |
2005-01-01 |
Idenix Cayman Ltd |
Modified 2' and 3'-nucleoside prodrugs for treating flaviviridae
|
AU2003239774A1
(en)
*
|
2002-07-03 |
2004-01-23 |
Maxygen Holdings Ltd. |
Full-length interferon gamma polypeptide variants
|
EP1526872A1
(en)
*
|
2002-07-24 |
2005-05-04 |
F. Hoffmann-La Roche Ag |
Polyalkylene glycol acid additives
|
US8968730B2
(en)
*
|
2002-08-14 |
2015-03-03 |
Macrogenics Inc. |
FcγRIIB specific antibodies and methods of use thereof
|
US8946387B2
(en)
*
|
2002-08-14 |
2015-02-03 |
Macrogenics, Inc. |
FcγRIIB specific antibodies and methods of use thereof
|
US8193318B2
(en)
*
|
2002-08-14 |
2012-06-05 |
Macrogenics, Inc. |
FcγRIIB specific antibodies and methods of use thereof
|
AU2003262650B2
(en)
*
|
2002-08-14 |
2009-10-29 |
Macrogenics, Inc. |
FcgammaRIIB-specific antibodies and methods of use thereof
|
US8044180B2
(en)
*
|
2002-08-14 |
2011-10-25 |
Macrogenics, Inc. |
FcγRIIB specific antibodies and methods of use thereof
|
CA2497777A1
(en)
*
|
2002-09-05 |
2004-03-18 |
The General Hospital Corporation |
Modified asialo-interferons and uses thereof
|
US8129330B2
(en)
|
2002-09-30 |
2012-03-06 |
Mountain View Pharmaceuticals, Inc. |
Polymer conjugates with decreased antigenicity, methods of preparation and uses thereof
|
US20040062748A1
(en)
|
2002-09-30 |
2004-04-01 |
Mountain View Pharmaceuticals, Inc. |
Polymer conjugates with decreased antigenicity, methods of preparation and uses thereof
|
BRPI0316646A8
(pt)
|
2002-11-25 |
2018-04-24 |
Sciclone Pharmaceuticals Inc |
método de proteção contra os danos causados pela radiação utilizando timosina alfa
|
PT1667708E
(pt)
*
|
2002-12-26 |
2012-09-14 |
Mountain View Pharmaceuticals |
Conjugados de interferão-beta-1b e polietileno glicol apresentando uma potência biológica in vitro aumentada
|
EA013535B1
(ru)
*
|
2002-12-26 |
2010-06-30 |
Маунтин Вью Фамэсьютикэлс, Инк. |
Полимерный конъюгат биоактивного компонента (варианты), способ его получения и использования, фармацевтические продукты на его основе
|
WO2004063351A2
(en)
*
|
2003-01-09 |
2004-07-29 |
Macrogenics, Inc. |
IDENTIFICATION AND ENGINEERING OF ANTIBODIES WITH VARIANT Fc REGIONS AND METHODS OF USING SAME
|
US7960512B2
(en)
*
|
2003-01-09 |
2011-06-14 |
Macrogenics, Inc. |
Identification and engineering of antibodies with variant Fc regions and methods of using same
|
US20070077225A1
(en)
*
|
2003-02-28 |
2007-04-05 |
Blatt Lawrence M |
Continuous delivery methods for treating hepatitis virus infection
|
CA2734066A1
(en)
|
2003-05-30 |
2005-01-13 |
Pharmasset, Inc. |
Modified fluorinated nucleoside analogues
|
WO2005014655A2
(en)
|
2003-08-08 |
2005-02-17 |
Fresenius Kabi Deutschland Gmbh |
Conjugates of hydroxyalkyl starch and a protein
|
GB0320638D0
(en)
|
2003-09-03 |
2003-10-01 |
Novartis Ag |
Organic compounds
|
CN102516386A
(zh)
|
2003-10-10 |
2012-06-27 |
诺沃挪第克公司 |
Il-21衍生物
|
PL1680137T3
(pl)
|
2003-10-14 |
2013-04-30 |
F Hoffmann La Roche Ltd |
Makrocykliczny kwas karboksylowy i związek acylosulfonamidowy jako inhibitor replikacji HCV
|
EP2633866A3
(en)
|
2003-10-17 |
2013-12-18 |
Novo Nordisk A/S |
Combination therapy
|
JP4982183B2
(ja)
|
2003-12-12 |
2012-07-25 |
ジェネンコー・インターナショナル・インク |
Cab分子
|
CN103755800B
(zh)
|
2004-02-02 |
2016-02-24 |
Ambrx公司 |
经修饰的人类生长激素多肽与其用途
|
US20090214472A1
(en)
*
|
2004-03-01 |
2009-08-27 |
Enzon Pharmaceuticals Inc. |
Interferon-beta polymer conjugates
|
US8088609B2
(en)
|
2004-04-15 |
2012-01-03 |
Danisco Us Inc. |
CAB molecules
|
WO2005115452A2
(en)
*
|
2004-04-16 |
2005-12-08 |
Macrogenics, Inc. |
Fcϝriib-specific antibodies and methods of use thereof
|
CA2565874C
(en)
*
|
2004-05-10 |
2017-10-03 |
Macrogenics, Inc. |
Humanized fc.gamma.riib-specific antibodies and methods of use thereof
|
BRPI0512235A
(pt)
|
2004-06-18 |
2008-02-19 |
Ambrx Inc |
polipeptìdeos ligadores de antìgenos e seus usos
|
US20080233100A1
(en)
*
|
2004-06-30 |
2008-09-25 |
Yiyou Chen |
Targeted enzymes
|
CN101023094B
(zh)
*
|
2004-07-21 |
2011-05-18 |
法莫赛特股份有限公司 |
烷基取代的2-脱氧-2-氟代-d-呋喃核糖基嘧啶和嘌呤及其衍生物的制备
|
AU2005272862B2
(en)
|
2004-08-12 |
2011-03-10 |
Merck Sharp & Dohme Corp. |
Stable pegylated interferon formulation
|
AU2005285045B2
(en)
*
|
2004-09-14 |
2011-10-13 |
Gilead Pharmasset Llc |
Preparation of 2'fluoro-2'- alkyl- substituted or other optionally substituted ribofuranosyl pyrimidines and purines and their derivatives
|
WO2007024249A2
(en)
|
2004-11-10 |
2007-03-01 |
Macrogenics, Inc. |
Engineering fc antibody regions to confer effector function
|
US20080044400A1
(en)
*
|
2004-12-09 |
2008-02-21 |
Volker Schellenberger |
Targeted enzyme prodrug therapy
|
CN103290084A
(zh)
|
2004-12-22 |
2013-09-11 |
Ambrx公司 |
表达和纯化重组人类生长激素的方法
|
CN102732588B
(zh)
|
2004-12-22 |
2015-01-07 |
Ambrx公司 |
氨酰基-tRNA合成酶的组合物及其用途
|
SG161209A1
(en)
|
2004-12-22 |
2010-05-27 |
Ambrx Inc |
Formulations of human growth hormone comprising a non-naturally encoded amino acid
|
CN103690936A
(zh)
|
2004-12-22 |
2014-04-02 |
Ambrx公司 |
经修饰的人类生长激素
|
US7365127B2
(en)
*
|
2005-02-04 |
2008-04-29 |
Enzon Pharmaceuticals, Inc. |
Process for the preparation of polymer conjugates
|
ES2538357T3
(es)
|
2005-04-11 |
2015-06-19 |
Crealta Pharmaceuticals Llc |
Formas variantes de urato oxidasa y uso de las mismas
|
JP5330826B2
(ja)
|
2005-04-28 |
2013-10-30 |
ジェネンコー・インターナショナル・インク |
Tab分子
|
KR20080026135A
(ko)
|
2005-06-03 |
2008-03-24 |
암브룩스, 인코포레이티드 |
개선된 인간 인터페론 분자 및 이의 용도
|
JP2008546708A
(ja)
|
2005-06-17 |
2008-12-25 |
ノバルティス アクチエンゲゼルシャフト |
Hcvにおけるサングリフェリンの使用
|
EP1893632B1
(en)
|
2005-06-17 |
2015-08-12 |
Novo Nordisk Health Care AG |
Selective reduction and derivatization of engineered factor vii proteins comprising at least one non-native cysteine
|
US7695710B2
(en)
*
|
2005-06-20 |
2010-04-13 |
Pepgen Corporation |
Antitumor and antiviral combination therapies using low-toxicity, long-circulating human interferon-alpha analogs
|
WO2007002233A2
(en)
*
|
2005-06-20 |
2007-01-04 |
Pepgen Corporation |
Low-toxicity, long-circulating chimeras of human interferon- alpha analogs and interferon tau
|
JP5249028B2
(ja)
|
2005-07-25 |
2013-07-31 |
インターミューン・インコーポレーテッド |
C型肝炎ウイルス複製の新規大環状阻害剤
|
PT1919503E
(pt)
|
2005-08-10 |
2015-01-05 |
Macrogenics Inc |
Identificação e manipulação de anticorpos com a regiões de fc variantes e métodos de utilização dos mesmos
|
EP1999129B1
(en)
|
2005-10-11 |
2010-12-29 |
Intermune, Inc. |
Compounds and methods for inhibiting hepatitis c viral replication
|
JP2009520949A
(ja)
|
2005-11-16 |
2009-05-28 |
アンブルックス,インコーポレイテッド |
非天然アミノ酸を含んでいる組成物および方法
|
EP1999470A4
(en)
*
|
2006-03-10 |
2009-08-19 |
Macrogenics Inc |
IDENTIFICATION AND GENETIC MODIFICATION OF ANTIBODIES WITH HEAVY CHAINS OF VARIANTS AND METHODS OF USE THEREOF
|
KR101059593B1
(ko)
|
2006-04-11 |
2011-08-25 |
노파르티스 아게 |
Hcv/hiv 억제제 및 이들의 용도
|
US20080096819A1
(en)
|
2006-05-02 |
2008-04-24 |
Allozyne, Inc. |
Amino acid substituted molecules
|
US7632492B2
(en)
|
2006-05-02 |
2009-12-15 |
Allozyne, Inc. |
Modified human interferon-β polypeptides
|
JP2009537609A
(ja)
|
2006-05-24 |
2009-10-29 |
ノボ ノルディスク ヘルス ケア アーゲー |
延長されたfixアナログ及び誘導体
|
ES2489646T3
(es)
*
|
2006-05-26 |
2014-09-02 |
Macrogenics, Inc. |
Anticuerpos humanizados específicos a Fc gamma RIIB y sus métodos de uso
|
WO2008002933A2
(en)
|
2006-06-26 |
2008-01-03 |
Macrogenics, Inc. |
Combination of fcgammariib antibodies and cd20-specific antibodies and methods of use thereof
|
SI2029173T1
(sl)
*
|
2006-06-26 |
2016-12-30 |
Macrogenics, Inc. |
Protitelesa, specifična za Fc RIIB, in postopki za njihovo uporabo
|
CN106008699A
(zh)
|
2006-09-08 |
2016-10-12 |
Ambrx公司 |
经修饰的人类血浆多肽或Fc骨架和其用途
|
CA2662755C
(en)
|
2006-09-08 |
2017-04-04 |
Ambrx, Inc. |
Suppressor trna transcription in vertebrate cells
|
ES2457527T3
(es)
|
2006-09-08 |
2014-04-28 |
Ambrx, Inc. |
ARNt Supresor hibrido en células de vertebrados
|
DE602007010499D1
(de)
*
|
2006-09-29 |
2010-12-23 |
Canji Inc |
Verfahren und zusammensetzungen für gentherapie
|
US20080112961A1
(en)
*
|
2006-10-09 |
2008-05-15 |
Macrogenics, Inc. |
Identification and Engineering of Antibodies with Variant Fc Regions and Methods of Using Same
|
PL2097068T3
(pl)
*
|
2006-11-24 |
2013-12-31 |
Cadila Healthcare Ltd |
Preparaty koniugatów PEG-interferon alfa
|
US8652466B2
(en)
|
2006-12-08 |
2014-02-18 |
Macrogenics, Inc. |
Methods for the treatment of disease using immunoglobulins having Fc regions with altered affinities for FcγRactivating and FcγRinhibiting
|
CA2682147C
(en)
|
2007-03-30 |
2017-08-08 |
Ambrx, Inc. |
Modified fgf-21 polypeptides and their uses
|
US7964580B2
(en)
|
2007-03-30 |
2011-06-21 |
Pharmasset, Inc. |
Nucleoside phosphoramidate prodrugs
|
WO2008137471A2
(en)
|
2007-05-02 |
2008-11-13 |
Ambrx, Inc. |
Modified interferon beta polypeptides and their uses
|
US7625555B2
(en)
*
|
2007-06-18 |
2009-12-01 |
Novagen Holding Corporation |
Recombinant human interferon-like proteins
|
WO2009151717A2
(en)
|
2008-04-02 |
2009-12-17 |
Macrogenics, Inc. |
Bcr-complex-specific antibodies and methods of using same
|
CA2707840A1
(en)
|
2007-08-20 |
2009-02-26 |
Allozyne, Inc. |
Amino acid substituted molecules
|
WO2009028573A1
(ja)
|
2007-08-27 |
2009-03-05 |
National University Corporation Nagoya University |
血液凝固障害におけるリバビリンの利用
|
CA2702637A1
(en)
|
2007-10-22 |
2009-04-30 |
Schering Corporation |
Fully human anti-vegf antibodies and methods of using
|
NZ603812A
(en)
|
2007-11-20 |
2014-06-27 |
Ambrx Inc |
Modified insulin polypeptides and their uses
|
MX2010008632A
(es)
|
2008-02-08 |
2010-08-30 |
Ambrx Inc |
Leptina-polipeptidos modificados y sus usos.
|
TW200946541A
(en)
|
2008-03-27 |
2009-11-16 |
Idenix Pharmaceuticals Inc |
Solid forms of an anti-HIV phosphoindole compound
|
BRPI0906309A2
(pt)
|
2008-04-02 |
2020-05-26 |
Macrogenics, Inc |
Imunoglobulina, anticorpo, uso do anticorpo e composição farmacêutica
|
EP2282770B1
(en)
*
|
2008-06-04 |
2018-03-07 |
MacroGenics, Inc. |
Antibodies with altered binding to fcrn and methods of using same
|
US8173621B2
(en)
*
|
2008-06-11 |
2012-05-08 |
Gilead Pharmasset Llc |
Nucleoside cyclicphosphates
|
JP5675606B2
(ja)
|
2008-07-08 |
2015-02-25 |
ボード・オブ・リージエンツ,ザ・ユニバーシテイ・オブ・テキサス・システム |
シグナル伝達性転写因子(stat)の増殖及び活性化の新規の抑制剤
|
EP2318029B1
(en)
|
2008-07-23 |
2017-11-01 |
Ambrx, Inc. |
Modified bovine g-csf polypeptides and their uses
|
KR101647164B1
(ko)
|
2008-09-26 |
2016-08-09 |
암브룩스, 인코포레이티드 |
변형된 동물 에리트로포이에틴 폴리펩티드 및 이의 용도
|
CA2738033C
(en)
|
2008-09-26 |
2019-11-26 |
Ambrx, Inc. |
Non-natural amino acid replication-dependent microorganisms and vaccines
|
SG172359A1
(en)
|
2008-12-23 |
2011-07-28 |
Pharmasset Inc |
Nucleoside phosphoramidates
|
KR20110104074A
(ko)
|
2008-12-23 |
2011-09-21 |
파마셋 인코포레이티드 |
퓨린 뉴클레오시드의 합성
|
BRPI0922508A8
(pt)
|
2008-12-23 |
2016-01-19 |
Pharmasset Inc |
Análogos de nucleosídeo
|
US8512690B2
(en)
|
2009-04-10 |
2013-08-20 |
Novartis Ag |
Derivatised proline containing peptide compounds as protease inhibitors
|
US20110182850A1
(en)
|
2009-04-10 |
2011-07-28 |
Trixi Brandl |
Organic compounds and their uses
|
TWI598358B
(zh)
*
|
2009-05-20 |
2017-09-11 |
基利法瑪席特有限責任公司 |
核苷磷醯胺
|
US8618076B2
(en)
|
2009-05-20 |
2013-12-31 |
Gilead Pharmasset Llc |
Nucleoside phosphoramidates
|
US9377454B2
(en)
|
2009-06-25 |
2016-06-28 |
Crealta Pharmaceuticals Llc |
Methods and kits for predicting infusion reaction risk and antibody-mediated loss of response by monitoring serum uric acid during pegylated uricase therapy
|
US20110027229A1
(en)
|
2009-07-31 |
2011-02-03 |
Medtronic, Inc. |
Continuous subcutaneous administration of interferon-alpha to hepatitis c infected patients
|
TR201804897T4
(tr)
|
2009-10-07 |
2018-06-21 |
Macrogenics Inc |
Fukosi̇lasyon ölçüsünün deği̇şi̇mleri̇nden dolayi geli̇şmi̇ş efektör i̇şlevi̇ sergi̇leyen fc bölgesi̇ni̇ i̇çeren poli̇pepti̇tler ve bunlarin kullanimlarina yöneli̇k yöntemler
|
EA201200650A1
(ru)
|
2009-10-30 |
2012-12-28 |
Бёрингер Ингельхайм Интернациональ Гмбх |
Курсы комбинированного лечения вируса гепатита с, включающие bi201335, интерферон-альфа и рибавирин
|
CN102666578A
(zh)
|
2009-12-21 |
2012-09-12 |
Ambrx公司 |
经过修饰的猪促生长素多肽和其用途
|
PE20121707A1
(es)
|
2009-12-21 |
2012-12-17 |
Ambrx Inc |
Polipeptidos de somatotropina bovina modificados y sus usos
|
PH12018501083A1
(en)
|
2010-03-04 |
2019-02-18 |
Macrogenics Inc |
Antibodies reactive with b7-h3, immunologically active fragments thereof and uses thereof
|
US8802091B2
(en)
|
2010-03-04 |
2014-08-12 |
Macrogenics, Inc. |
Antibodies reactive with B7-H3 and uses thereof
|
WO2011107591A1
(en)
|
2010-03-05 |
2011-09-09 |
Rigshospitalet |
Chimeric inhibitor molecules of complement activation
|
PT2752422T
(pt)
|
2010-03-31 |
2017-11-07 |
Gilead Pharmasset Llc |
Síntese estereosseletiva de princípios ativos contendo fósforo
|
PL3290428T3
(pl)
|
2010-03-31 |
2022-02-07 |
Gilead Pharmasset Llc |
Tabletka zawierająca krystaliczny (S)-2-(((S)-(((2R,3R,4R,5R)-5-(2,4-diokso-3,4-dihydropirymidyn-1(2H)-ylo)-4-fluoro-3-hydroksy-4-metylotetrahydrofuran-2-ylo)metoksy)(fenoksy)fosforylo)amino)propanian izopropylu
|
EP2569331A1
(en)
|
2010-05-10 |
2013-03-20 |
Perseid Therapeutics LLC |
Polypeptide inhibitors of vla4
|
CN102711871A
(zh)
|
2010-06-16 |
2012-10-03 |
麦德托尼克公司 |
用于稳定药物递送装置中的药物的阻尼***
|
BR112012033022A2
(pt)
|
2010-06-24 |
2016-12-20 |
Genosciense Pharma Sas |
tratamento de vírus de hepatite c relacionado a doenças utilizando hidroxicloroquina ou uma combinação de hidroxicloroquina e um agente antiviral
|
RS59193B1
(sr)
|
2010-08-17 |
2019-10-31 |
Ambrx Inc |
Modifikovani polipeptidi relaksina i njihova primena
|
US9567386B2
(en)
|
2010-08-17 |
2017-02-14 |
Ambrx, Inc. |
Therapeutic uses of modified relaxin polypeptides
|
TWI480288B
(zh)
|
2010-09-23 |
2015-04-11 |
Lilly Co Eli |
牛顆粒細胞群落刺激因子及其變體之調配物
|
US20130225483A1
(en)
|
2010-10-05 |
2013-08-29 |
Claudio Avila |
New Treatments of Hepatitis C Virus Infection
|
EA201390532A1
(ru)
|
2010-10-08 |
2013-09-30 |
Новартис Аг |
Композиции сульфамидых ингибиторов ns3, содержащие витамин е
|
MX2013006052A
(es)
|
2010-11-30 |
2013-06-18 |
Novartis Ag |
Nuevos tratamientos de la infeccion por el virus de hepatitis c.
|
PT3042910T
(pt)
|
2010-11-30 |
2019-04-16 |
Gilead Pharmasset Llc |
2'-espiro-nucleósidos para utilização na terapia da hepatite c
|
KR20140007927A
(ko)
|
2011-03-31 |
2014-01-20 |
노파르티스 아게 |
C형 간염 바이러스 감염을 치료하기 위한 알리스포리비르
|
DK2694087T3
(en)
|
2011-04-01 |
2015-04-13 |
Novartis Ag |
The treatment of infection with Hepatitis B virus alone or in combination with hepatitis delta virus, and in connection with liver diseases
|
US20150104415A1
(en)
|
2011-04-13 |
2015-04-16 |
Debiopharm International Sa |
Treatments of Hepatitis C virus infection
|
WO2013004607A1
(en)
|
2011-07-01 |
2013-01-10 |
Bayer Intellectual Property Gmbh |
Relaxin fusion polypeptides and uses thereof
|
WO2013024156A2
(en)
|
2011-08-17 |
2013-02-21 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Combinations of anti-hcv-entry factor antibodies and interferons for the treatment and the prevention of hcv infection
|
WO2013024158A1
(en)
|
2011-08-17 |
2013-02-21 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Combinations of protein kinase inhibitors and interferons or of protein kinase inhibitors and direct acting antivirals for the treatment and the prevention of hcv infection
|
CN103826654A
(zh)
|
2011-09-27 |
2014-05-28 |
诺华股份有限公司 |
用于治疗丙型肝炎病毒感染的阿拉泊韦
|
US8889159B2
(en)
|
2011-11-29 |
2014-11-18 |
Gilead Pharmasset Llc |
Compositions and methods for treating hepatitis C virus
|
WO2013137869A1
(en)
|
2012-03-14 |
2013-09-19 |
Boehringer Ingelheim International Gmbh |
Combination therapy for treating hcv infection in an hcv-hiv coinfected patient population
|
JP2015512900A
(ja)
|
2012-03-28 |
2015-04-30 |
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング |
特別な患者の遺伝子亜型分集団のhcv感染症を治療するための併用療法
|
CN104583235B
(zh)
|
2012-06-08 |
2019-03-01 |
苏特罗生物制药公司 |
含位点特异非天然氨基酸残基的抗体、其制备和使用方法
|
US9732161B2
(en)
|
2012-06-26 |
2017-08-15 |
Sutro Biopharma, Inc. |
Modified Fc proteins comprising site-specific non-natural amino acid residues, conjugates of the same, methods of their preparation and methods of their use
|
CN102716469B
(zh)
*
|
2012-07-07 |
2013-09-11 |
北京三元基因工程有限公司 |
干扰素α的干粉吸入剂
|
ES2907763T3
(es)
|
2012-08-31 |
2022-04-26 |
Sutro Biopharma Inc |
Aminoácidos modificados que comprenden un grupo azido
|
WO2014033266A1
(en)
|
2012-08-31 |
2014-03-06 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Anti-sr-bi antibodies for the inhibition of hepatitis c virus infection
|
US20140205566A1
(en)
|
2012-11-30 |
2014-07-24 |
Novartis Ag |
Cyclic nucleuoside derivatives and uses thereof
|
US9487587B2
(en)
|
2013-03-05 |
2016-11-08 |
Macrogenics, Inc. |
Bispecific molecules that are immunoreactive with immune effector cells of a companion animal that express an activating receptor and cells that express B7-H3 and uses thereof
|
ES2865473T3
(es)
|
2013-07-10 |
2021-10-15 |
Sutro Biopharma Inc |
Anticuerpos que comprenden múltiples residuos de aminoácidos no naturales sitio-específicos, métodos para su preparación y métodos de uso
|
PL3038601T3
(pl)
|
2013-08-27 |
2020-08-24 |
Gilead Pharmasset Llc |
Formulacja złożona dwóch związków przeciwwirusowych
|
WO2015054658A1
(en)
|
2013-10-11 |
2015-04-16 |
Sutro Biopharma, Inc. |
Modified amino acids comprising tetrazine functional groups, methods of preparation, and methods of their use
|
US9388239B2
(en)
|
2014-05-01 |
2016-07-12 |
Consejo Nacional De Investigation Cientifica |
Anti-human VEGF antibodies with unusually strong binding affinity to human VEGF-A and cross reactivity to human VEGF-B
|
MX2017002140A
(es)
|
2014-08-19 |
2017-08-21 |
Biogen Ma Inc |
Metodo de pegilacion.
|
TW202124419A
(zh)
|
2014-10-24 |
2021-07-01 |
美商必治妥美雅史谷比公司 |
經修飾之fgf-21多肽及其用途
|
KR102181168B1
(ko)
|
2015-11-03 |
2020-11-23 |
에프. 호프만-라 로슈 아게 |
Hbv 캡시드 조립 억제제와 인터페론의 조합 치료
|
WO2017180813A1
(en)
|
2016-04-15 |
2017-10-19 |
Macrogenics, Inc. |
Novel b7-h3 binding molecules, antibody drug conjugates thereof and methods of use thereof
|
NZ749962A
(en)
*
|
2016-06-20 |
2020-06-26 |
Elanco Us Inc |
Pegylated porcine interferon and methods of use thereof
|
WO2018087345A1
(en)
|
2016-11-14 |
2018-05-17 |
F. Hoffmann-La Roche Ag |
COMBINATION THERAPY OF AN HBsAg INHIBITOR, A NUCLEOS(T)IDE ANALOGUE AND AN INTERFERON
|
WO2018148419A1
(en)
|
2017-02-08 |
2018-08-16 |
Bristol-Myers Squibb Company |
Modified relaxin polypeptides comprising a pharmacokinetic enhancer and uses thereof
|
AU2019337610A1
(en)
|
2018-09-11 |
2021-05-06 |
Ambrx, Inc. |
Interleukin-2 polypeptide conjugates and their uses
|
AU2019361206A1
(en)
|
2018-10-19 |
2021-06-03 |
Ambrx, Inc. |
Interleukin-10 polypeptide conjugates, dimers thereof, and their uses
|
MX2021009644A
(es)
|
2019-02-12 |
2021-09-08 |
Ambrx Inc |
Composiciones que contienen, metodos y usos de conjugados de anticuerpo-agonista de tlr.
|
JP2023517595A
(ja)
|
2020-03-11 |
2023-04-26 |
アンブルックス,インコーポレイテッド |
インターロイキン-2ポリペプチド結合物およびその使用方法
|
AU2021327396A1
(en)
|
2020-08-20 |
2023-03-23 |
Ambrx, Inc. |
Antibody-TLR agonist conjugates, methods and uses thereof
|
IL307282A
(en)
|
2021-04-03 |
2023-11-01 |
Ambrx Inc |
Antidote conjugates against HER2 and their applications
|